

Electronic Acknowledgement Receipt

EFS ID:	9626401
Application Number:	10597803
International Application Number:	
Confirmation Number:	6534
Title of Invention:	Dihydrotetrabenazines And Pharmaceutical Compositions Containing Them
First Named Inventor/Applicant Name:	Robert Tridgett
Customer Number:	21186
Filer:	Gregory W. Smock/Patrick McNally
Filer Authorized By:	Gregory W. Smock
Attorney Docket Number:	3063.002US1
Receipt Date:	09-MAR-2011
Filing Date:	13-APR-2007
Time Stamp:	21:37:05
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		10597803_SIDS_03-09-11.pdf	116479 791a5eae8dc6eb8867f971fe10214966105e6ae	yes	9

	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Miscellaneous Incoming Letter		1	1	
	Miscellaneous Incoming Letter		2	3	
	Transmittal Letter		4	5	
	Information Disclosure Statement (IDS) Filed (SB/08)		6	9	
Warnings:					
Information:					
2	Foreign Reference	0001_gb2410947a.pdf	8028752	no	58
			56e7d24fc30e8af4b79d7732194c10c174dde42b		
Warnings:					
Information:					
3	Foreign Reference	0002_gb2463452a.pdf	8331277	no	70
			4173f60a1ec0ea2193ffc2c710b3c7304ddda82d		
Warnings:					
Information:					
4	Foreign Reference	0003_wo2006069030a1.pdf	3260928	no	57
			ca8d87700cff36c54c08fafee1834985ce242a8		
Warnings:					
Information:					
5	Foreign Reference	0004_wo2008079404a2.pdf	13821746	no	258
			1be949d5223f5c9aed11b336fbfdb6cb225b4a2a		
Warnings:					
Information:					
6	Foreign Reference	0005_wo2009150474a1.pdf	2906375	no	49
			793c48be4ec032442ccf9656798fcd444ff4a3d		
Warnings:					
Information:					
7	Foreign Reference	0006_11019956.pdf	12531196	no	280
			807458904f0c8b55ead2867834166674c2d7f9e1		
Warnings:					
Information:					

8	NPL Documents	0007_macdonald__a_novel_gene_taining_a_trinucleotide_repeat.pdf	3794709	no	13
			6802f9e29fe42a1dae462b7b3f8332d68f951fce		
Warnings:					
Information:					
9	NPL Documents	0008_3063010us1_312amdt_111610.pdf	752261	no	8
			df7c2ef37b9fcc726b682d9b4351a5f61c55c70		
Warnings:					
Information:					
10	NPL Documents	0009_3063010us1_noar_010611.pdf	1300287	no	7
			15efc8cd22c93b470251840244663837acb12703		
Warnings:					
Information:					
11	NPL Documents	0010_p3063010us1_noa1.pdf	1454121	no	8
			ace3942517823029ee79540187231d56c5cc809f		
Warnings:					
Information:					
12	NPL Documents	0011_3063026us1_pamd_121010.pdf	441148	no	5
			f2419bf15dceef9c8a253c2a424ef08856c8a7a1		
Warnings:					
Information:					
13	NPL Documents	0012_3063025us1_isrwo_100810.pdf	2831139	no	14
			e24a319de97fd56b0f3e2458c50f0ee96c274675		
Warnings:					
Information:					
14	NPL Documents	0013_abrahamsson.pdf	1800448	no	6
			9388d66b349795f56560a822c4ed7ff3dfe5bde		
Warnings:					
Information:					
15	NPL Documents	0015_bengamin__proceed_with_care_direct_predictive_for.pdf	4164925	no	12
			de9ab8d362bad144d026409c7250e75a17f1945f		
Warnings:					
Information:					
16	NPL Documents	0016_bennett__an_icam1_antisense_oligonucleotide_prevents_and_reverses.pdf	343540	no	13
			d81df0a13424627ef3bf509a6253d8368c0d7450		
Warnings:					
Information:					

17	NPL Documents	0017_sr31747a_is_a_sigma_receptor_ligand_exhibiting_antitumoural_activity_both_in_vitro.pdf	148992	no	9
			13ed446c37d1382e4edfdd69e2304fadefdd65c70		
Warnings:					
Information:					
18	NPL Documents	0018_development_of_a_competitive_antagonist_for_the.pdf	7076073	no	23
			dfe51130751754a55b2a9512b0527f35005bf9cf		
Warnings:					
Information:					
19	NPL Documents	0019_the_pharmacology_and_distribution_of_human_5hydroxytryptamine2b.pdf	2279778	no	7
			ea7c2152a0dfe795175fbc04a3d0e9d7e8e5fbfd		
Warnings:					
Information:					
20	NPL Documents	0020_sigma_binding_site_ligands_inhibit_cell_proliferation_in_mammary.pdf	2842940	no	10
			4dc2fbce4ad5531e88894052aa092b1f404903db		
Warnings:					
Information:					
21	NPL Documents	0014_aspartate_binding_to_glutamate_uptake_sites_in_striatal_and_a.pdf	60101	no	4
			b9b2bfdd2cae0cbfd3a9e094c00f5a5f9d7719d8		
Warnings:					
Information:					
22	NPL Documents	0021_the_likelihood_of_being_affected_with_huntington_disease.pdf	2691581	no	9
			e89e408754b81e3f833b93fec82038170e5a49cd		
Warnings:					
Information:					
23	NPL Documents	0022_alpha2adrenoceptor_subtypes_and_imidazolinelike_binding.pdf	2157395	no	7
			95855f73d7e16b59adb7a6baaa8bf75d3c26af4b		
Warnings:					
Information:					
24	NPL Documents	0023_color.pdf	801923	no	4
			2d0e66d1bb2ba16db4482826914f54f805e73d02		
Warnings:					
Information:					
25	NPL Documents	0024_sigma2_receptor_agonists_activate_a_novel_apoptotic.pdf	296197	no	10
			a134cdeba8e45f276e800716ca562a4eaa28e993		
Warnings:					
Information:					

26	NPL Documents	0025_pnas_1996_93_10_51665171.pdf	2238927	no	6
			9cd798d32be0d81c62bc2681f9db5ac5e6935068		
Warnings:					
Information:					
27	NPL Documents	0026_molecular_and_ligandbinding_characterization_of_the_sigmareceptor.pdf	239191	no	10
			5fc1772305fe395fd37e6280f7da27965d4c24fd		
Warnings:					
Information:					
28	NPL Documents	0027_grayson_pa55_2004.pdf	1197900	no	3
			f6a8208d358dc6f0af695801642ce759b48851f2		
Warnings:					
Information:					
29	NPL Documents	0028_grayson_p31_2007.pdf	328932	no	8
			4efff502dc42d0c279f92817e843a872aca787ed		
Warnings:					
Information:					
30	NPL Documents	0029_stable_expression_of_biogenic_amine_transporter.pdf	2326548	no	7
			e37c0976dfdb28e445e3d5bfa6ee0b9d7702bdd3		
Warnings:					
Information:					
31	NPL Documents	0030_cellular_adhesion_molecules_in_rat_adjuvant_arthritis.pdf	2749333	no	10
			84a7332c1f65ff73cfa01674ea7c74a6683f18d2		
Warnings:					
Information:					
32	NPL Documents	0031_purification_molecular_cloning_and_expression_of_the_mammalian.pdf	2491926	no	6
			eec43626dc3640f86e9e9e1797e918e030071636		
Warnings:					
Information:					
33	NPL Documents	0032_hashimoto_p159_1993.pdf	1462034	no	5
			5cd536e448a84d29aacffbdcc8ecb1c2e1682c		
Warnings:					
Information:					
34	NPL Documents	0033_relevance_of_new_psychotropic_drugs_for_the_neurologist.pdf	79137	no	5
			6a68a847a0254d5f4626f82e4ecba152d116a274		
Warnings:					
Information:					

35	NPL Documents	0034_the_evolution_of_the_serotoninindopamine_antagonist_cept.pdf	3979275 1b54a024f754ee2dee2af12df371e27d6ed2c32f	no	8
Warnings:					
Information:					
36	NPL Documents	0035_idris_2005.pdf	35838 3e2c05e0e29f30a35539c311cd9a40734eb2e793	no	1
Warnings:					
Information:					
37	NPL Documents	0036_the_neuropsychopharmacology_of_phencyclidine.pdf	143962 fd66a32055fceb70da66348ccf64e2b0fa09add	no	25
Warnings:					
Information:					
38	NPL Documents	0038_toxicol_pathol1997knoerzer139.pdf	3494880 adecf085949a8e6cdf95ab42b21e628be779bcde	no	8
Warnings:					
Information:					
39	NPL Documents	0039_meltzer_p2s_1995.pdf	2230094 252da9ca3e92aa7b034027200d9d07189e537090	no	3
Warnings:					
Information:					
40	NPL Documents	0040_millan_specific_labelling_of_serotonin.pdf	173243 a2d2e166bf3fd9136ac5df5866f6d171b815be3f	no	10
Warnings:					
Information:					
41	NPL Documents	0037_karpuj__prolonged_survival_and_decreased_abnormal_movements_in_transgenic.pdf	586935 a9cd9ebffd98a44fcc38514116f377d470b57a3e	no	7
Warnings:					
Information:					
42	NPL Documents	0041_the_journal_of_neuroscience_2_july_2003_231358355845.pdf	2238978 415033c99d67bd830e0a4181528512f608c19756	no	6
Warnings:					
Information:					
43	NPL Documents	0042_near_p252_1986.pdf	2238990 1b4f5e5c2bfc6ec4d30bb0e71da9df2c74fdec99	no	6
Warnings:					
Information:					

44	NPL Documents	0043_a_novel_onestep_highly_sensitive_fluorometric_assay_to_evaluate_cell.pdf	353494	no	11
081cf8cc21691f05fe2df840e9d462bdf73187da					
Warnings:					
Information:					
45	NPL Documents	0044_interleukin_15_is_produced_by_endothelial_cells_and_increases_the_transendothelial.pdf	383305	no	12
c7eaa5df6eb93d20f3724d5f32af987def5d348					
Warnings:					
Information:					
46	NPL Documents	0045_scherman_1988_11311136.pdf	2026290	no	6
3eedc7fcfb209c56eb736e056f56746340d3a017					
Warnings:					
Information:					
47	NPL Documents	0046_streptococcal_cell_wallinduced_arthritis.pdf	109625	no	7
16a28bf648b7fb225c45050c94eab75a2a256d19					
Warnings:					
Information:					
48	NPL Documents	0047_small_molecule_antagonists_of_the_1_receptor_cause sele.pdf	867451	no	12
ea095393dba1e3fc8643648855840357ce1277ac7					
Warnings:					
Information:					
49	NPL Documents	0048_roland__jpet_2000.pdf	206442	no	7
022b3df297d6a5c961edf791225ae90ce9befe07					
Warnings:					
Information:					
50	NPL Documents	0049_a_preliminary_investigation_into_the_effects_of_ge.pdf	42231	no	1
05606cf60f7e42bb369dfe57fd32de553a2e2e98					
Warnings:					
Information:					
51	NPL Documents	0050_uhlen_p1558_1994.pdf	2888632	no	8
c11cc552450f183c233005c9d9bfa4507214b1afc					
Warnings:					
Information:					
52	NPL Documents	0051_3hrs79948197_binding_to_human_rat_guinea_pig_and_pig_a2a.pdf	189378	no	9
3e5f5c52e5647a8b1e15a78214df5ff757e9a5d					
Warnings:					
Information:					

53	NPL Documents	0052_expression_of_sigma_1_receptor_in_human_breast_cancer.pdf	251771 328c4f056c8fd1592d3082bd9aafb1a3f4d29466	no	10
Warnings:					
Information:					
54	NPL Documents	0053_wingstrand.pdf	981223 337ff87369c14f8dac1552759e9651c75f05e6db	no	4
Warnings:					
Information:					
55	NPL Documents	0054_characterization_of_high_affinity_tbzoh_binding.pdf	108110 5283602dc57b4f728d4a45ee6519fff54177895d	no	7
Warnings:					
Information:					
Total Files Size (in bytes):			120878386		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					